Brief: Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease

May 13 (Reuters) - Absci Corp ABSI.O:

ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF ABS-101, A POTENTIAL BEST-IN-CLASS ANTI-TL1A ANTIBODY FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2025

ABSCI CORP - ABS-101 SHOWS HIGH POTENCY AND QUARTERLY DOSING POTENTIAL

Source text: ID:nGNX5RX86F

Further company coverage: ABSI.O

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on AbSci

See all news